J R Berenson1,2,3, J D Hilger2, O Yellin2, R Dichmann4, D Patel-Donnelly5, R V Boccia6, A Bessudo7, L Stampleman8, D Gravenor9, S Eshaghian10, Y Nassir11, R A Swift3 and R A Vescio10 1Department of Hematology/Oncology, Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, USA 2Oncotherapeutics, West Hollywood, CA, USA 3James R Berenson, MD, Inc., West Hollywood, CA, USA 4Department of Medical Oncology and Hematology, Central Coast […]
March 1, 2017
Advances in the Management of Multiple Myeloma
James R Berenson, MD,abc Tanya M Spektor, PhD,c and James Wang, MDab aInstitute for Myeloma and Bone Cancer Research; bJames R Berenson, MD, Inc; and cOncotherapeutics, West Hollywood, California Correspondence: James R Berenson, MD; jberenson@imbcr.org. Disclosures: Dr Berenson is a consultant for and receives honoraria and research funding from Takeda, Amgen, Jansen, Celgene, and Bristol-Meyers-Squibb. […]
March 1, 2017
To Transplant or Not To Transplant in Multiple Myeloma
Clinical Advances in Hematology & Oncology Authors: James R. Berenson, MD, Claudia Andreu-Vieyra, PhD, Sergio Giralt, MD May 2014, Volume 12, Issue 5 High-dose therapy in combination with autologous stem cell transplantation (ASCT) has become the standard of care for younger multiple myeloma patients. Is ASCT still the best treatment for these patients in the […]
May 24, 2016
I Have WHAT? An Interview With Patient Advocate Debra Berenson
Interview with Debra Berenson, myeloma patient advocate, wife of myeloma expert Dr. James Berenson, and author of the book, I HAVE WHAT?. Debra has collected stories, insights, and tools for and from patients and their families with myeloma and related diseases. The second half of the book includes information and advice from doctors and other healthcare professionals who treat […]
July 17, 2015
IMBCR Identifies New Treatments for Myeloma in 2015!
First, we have made much progress on our new protein marker called B-cell maturation antigen (BCMA) that was initially found in the blood of myeloma patients. The level of this single serum marker predicts patient’s long-term outcomes. It also correlates with how the patient is doing in that very low levels are associated with patients […]
May 21, 2015
KIIS Cares Interview
What: Myeloma is a disease in your bone marrow. Inside your bone marrow are the cells that make your blood, your red cells, your white cells, and your platelets. This plays a key role in maintaining the strength of the bone. Why: There have been several recent breakthroughs for the treatment of multiple myeloma patients […]
April 13, 2015
Counterpoints: Do Patients With Multiple Myeloma Need Maintenance Treatment?
By Clinical Advances in Hematology & Oncology March 2015, Volume 13, Issue 3 Multiple myeloma is an incurable disease, and patients who respond to treatment eventually relapse—which makes long-term maintenance therapy an appealing option. But is a treatment with an unclear effect on overall survival worth the side effects and financial cost? In this month’s […]
February 6, 2015
Talking About Myeloma with Loved Ones
Do you feel the Love? The New Year is here. Perhaps you have been newly diagnosed? Whether a Myeloma warrior, or new to the world of MM, talking about the disease with loved ones can be difficult, at best. What is Multiple Myeloma anyway? It’s hard enough to understand the disease, let alone explain it! […]
December 18, 2014
Updates on Treatment
“How do you know if you are getting the right drugs at the right doses for treating your myeloma?”
James R. Berenson, MD
- President & CEO of Institute for Myeloma & Bone Cancer Research (IMBCR)
- President & CEO of Berensononcology
- Founder & President of Oncotherapeutics
- Founder & Principal of Oncotracker
- What Is Multiple Myeloma?
-
Video Updates
- Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- Outcomes in Multiple Myeloma Patients Evaluated
- Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
- Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
- Understanding Myeloma News About Secondary Cancers and Clotting
-
Dedication of “Determination”
March 5, 2017
0 Comments